Annual Drug Patent Expirations for TASIGNA
Tasigna is a drug marketed by Novartis
and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and forty-one patent family members in fifty countries.
The generic ingredient in TASIGNA is nilotinib hydrochloride monohydrate. One supplier is listed for this compound. Additional details are available on the nilotinib hydrochloride monohydrate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
or visit www.DrugPatentWatch.com